LCD-L39682
Document details
Summary
The introduction of the MolDX LCD for molecular testing of thyroid nodules may lead to increased billing opportunities for physicians who can now utilize these advanced tests for risk stratification.New Molecular Testing LCD for Thyroid Nodules by Noridian.
Affected codes
ICD-10-CM
Affected specialty
Endocrinology alerts →Source document
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39682&ver=8CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FR-2023-09188 · Endocrinology
The extension of in-person delivery flexibility for the MDPP until December 31, 2023, allows suppliers to adapt their services during ongoing transitions from the Public Health Emergency. This policy
View alertPolicy LCD-L33431 · Endocrinology
The new LCD for HbA1c testing could significantly alter billing practices for diabetes management, especially with Palmetto GBA as the contractor. Providers may need to adjust their coding and documen
View alertPolicy LCD-L38686 · Endocrinology
The implementation of the new LCD for Implantable Continuous Glucose Monitors (I-CGM) by WPS may affect billing processes for diabetes management services. Providers will need to familiarize themselve
View alertPolicy LCD-L36864 · Endocrinology
The implementation of GlycoMark® testing for glycemic control represents a significant change in billing practices, particularly for outpatient services. This may lead to supports compliance with updated rates oppor
View alert